91 related articles for article (PubMed ID: 16246554)
21. Diphenylpyrroles: Novel p53 activators.
Gomha SM; Eldebss TM; Abdulla MM; Mayhoub AS
Eur J Med Chem; 2014 Jul; 82():472-9. PubMed ID: 24934571
[TBL] [Abstract][Full Text] [Related]
22. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length.
Lai Z; Auger KR; Manubay CM; Copeland RA
Arch Biochem Biophys; 2000 Sep; 381(2):278-84. PubMed ID: 11032416
[TBL] [Abstract][Full Text] [Related]
23. Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors.
Lu F; Chi SW; Kim DH; Han KH; Kuntz ID; Guy RK
J Comb Chem; 2006; 8(3):315-25. PubMed ID: 16677000
[TBL] [Abstract][Full Text] [Related]
24. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P
ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983
[TBL] [Abstract][Full Text] [Related]
25. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.
Clement JA; Kitagaki J; Yang Y; Saucedo CJ; O'Keefe BR; Weissman AM; McKee TC; McMahon JB
Bioorg Med Chem; 2008 Dec; 16(23):10022-8. PubMed ID: 18977148
[TBL] [Abstract][Full Text] [Related]
26. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
Dickens MP; Roxburgh P; Hock A; Mezna M; Kellam B; Vousden KH; Fischer PM
Bioorg Med Chem; 2013 Nov; 21(22):6868-77. PubMed ID: 24113239
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
Carry JC; Garcia-Echeverria C
Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
[TBL] [Abstract][Full Text] [Related]
28. Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Mazars A; Fåhraeus R
Biotechnol J; 2010 Apr; 5(4):377-84. PubMed ID: 20235143
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
[TBL] [Abstract][Full Text] [Related]
30. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts.
Latonen L; Taya Y; Laiho M
Oncogene; 2001 Oct; 20(46):6784-93. PubMed ID: 11709713
[TBL] [Abstract][Full Text] [Related]
31. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway.
Hasan MK; Yaguchi T; Harada JI; Hirano T; Wadhwa R; Kaul SC
Int J Oncol; 2008 Mar; 32(3):663-71. PubMed ID: 18292944
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
Zhang R; Mayhood T; Lipari P; Wang Y; Durkin J; Syto R; Gesell J; McNemar C; Windsor W
Anal Biochem; 2004 Aug; 331(1):138-46. PubMed ID: 15246006
[TBL] [Abstract][Full Text] [Related]
33. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.
Lundholt BK; Heydorn A; Bjørn SP; Praestegaard M
Assay Drug Dev Technol; 2006 Dec; 4(6):679-88. PubMed ID: 17199506
[TBL] [Abstract][Full Text] [Related]
34. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
[TBL] [Abstract][Full Text] [Related]
35. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
Grasberger BL; Lu T; Schubert C; Parks DJ; Carver TE; Koblish HK; Cummings MD; LaFrance LV; Milkiewicz KL; Calvo RR; Maguire D; Lattanze J; Franks CF; Zhao S; Ramachandren K; Bylebyl GR; Zhang M; Manthey CL; Petrella EC; Pantoliano MW; Deckman IC; Spurlino JC; Maroney AC; Tomczuk BE; Molloy CJ; Bone RF
J Med Chem; 2005 Feb; 48(4):909-12. PubMed ID: 15715460
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.
Tian Y; Ma Y; Gibeau CR; Lahue BR; Shipps GW; Strickland C; Bogen SL
Bioorg Med Chem Lett; 2016 Jun; 26(11):2735-8. PubMed ID: 27080185
[TBL] [Abstract][Full Text] [Related]
37. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.
Yin H; Lee GI; Park HS; Payne GA; Rodriguez JM; Sebti SM; Hamilton AD
Angew Chem Int Ed Engl; 2005 Apr; 44(18):2704-2707. PubMed ID: 15765497
[No Abstract] [Full Text] [Related]
38. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
39. c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF.
Dias SS; Milne DM; Meek DW
Oncogene; 2006 Oct; 25(50):6666-71. PubMed ID: 16702947
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.
Raboisson P; Marugán JJ; Schubert C; Koblish HK; Lu T; Zhao S; Player MR; Maroney AC; Reed RL; Huebert ND; Lattanze J; Parks DJ; Cummings MD
Bioorg Med Chem Lett; 2005 Apr; 15(7):1857-61. PubMed ID: 15780621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
